Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 18/20 | 0.42 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | IL1B | P01584 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29348394 | 0.89 | DDB1 (0.43) | CRBNDDB1IKZF3BRD4ALDH1A1 | |
| SCHEMBL29348393 | 0.87 | CNR2 (0.42) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29348534 | 0.86 | DDB1 (0.42) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29348285 | 0.86 | DDB1 (0.41) | CRBNDDB1IKZF3BRD4CREBBP | |
| SCHEMBL29348509 | 0.86 | CRBN (0.40) | CRBNDDB1IKZF3 | |
| SCHEMBL29348551 | 0.85 | CRBN (0.43) | CRBNDDB1IKZF3 | |
| SCHEMBL29348556 | 0.83 | DDB1 (0.39) | CRBNDDB1 | |
| SCHEMBL29348549 | 0.83 | DDB1 (0.41) | CRBNDDB1BRD4CREBBP | |
| SCHEMBL29348602 | 0.83 | DDB1 (0.45) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29348424 | 0.81 | CRBN (0.45) | CRBNDDB1IKZF3BRD4CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |